Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 9:7:293-300.
doi: 10.2147/PPA.S40173. Print 2013.

Adherence to monthly online self-assessments for short-term monitoring: a 1-year study in relapsing-remitting multiple sclerosis patients after start of disease modifying treatment

Peter Joseph Jongen  1 , Evert Sanders, Cees Zwanikken, Jan Koeman, Leo H Visser, Petra Koopmans, Dirk Lehnick; OPTIVIT study group
Affiliations

Adherence to monthly online self-assessments for short-term monitoring: a 1-year study in relapsing-remitting multiple sclerosis patients after start of disease modifying treatment

Peter Joseph Jongen et al. Patient Prefer Adherence. .

Abstract

Background: The participation of neurologists and patients in studies on the effectiveness and safety of newly authorized drugs in multiple sclerosis (MS) is insufficient. Monthly online self-assessments using patient-reported outcomes may help in short-term monitoring of neurological changes and side effects.

Objective: Investigate in relapsing-remitting (RR) MS patients the adherence to monthly online self-assessments after the start of disease modifying treatment.

Methods: Observational study in 39 neurological departments in The Netherlands. Patients starting glatiramer acetate treatment were instructed to complete online the Modified Fatigue Impact Scale 5-item version and the 8-item Leeds Multiple Sclerosis Quality of Life scale every month during 1 year (T0 toT12).

Results: Sixty-three investigators included 163 analyzable patients. At T3, 148 (90.8%) patients had completed all questionnaires; at T6, 142 (87.1%); at T9, 133 (81.6%); and at T12, 123 (75.5%). Eight (4.9%) patients did not complete any questionnaire. Median values for inter-assessment intervals ranged from 32 to 34 days (first quartile [Q1] 30 days, third quartile [Q3] 41 days), and the final assessment was at 417 days (median: Q1 385 days, Q3 480 days). Forty-three (26.3%) patients completed the questionnaires at all time points (completion adherent) with their final assessment within 30 days after the scheduled T12 (interval adherent). Eighty (49.1%) patients were completion adherent, but not interval adherent. Forty (24.5%) patients were not completion adherent, as they discontinued assessments prematurely. Men were more interval adherent than women (47.5% vs 20.0%; P = 0.001).

Conclusion: The observation that three out of four (75.5%) RRMS patients completed two short questionnaires at all monthly time points during 1 year after the start of disease modifying treatment suggests that intensive online monitoring in this patient group is feasible. As only one in five (19.6%) patients adhered to the time intervals between self-assessments, measures are needed that improve the timely completion of questionnaires.

Keywords: LMSQoL; MFIS-5; effectiveness; fatigue; glatiramer acetate; health-related quality of life.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Screenshot of the five items of the MFIS-5 questionnaire. Copyright © 2012, Curavista bv, Geertruidenberg, Netherlands. Reprinted with permission. Notes: Questions: (1) Due to my fatigue I have been less alert. (2) Due to my fatigue I have been limited in my ability to do things away from home. (3) Due to my fatigue I have had trouble maintaining physical efforts for long periods. (4) Due to my fatigue I have been less able to complete tasks that require physical effort. (5) Due to my fatigue I have had trouble concentrating. Possible answers: never, seldom, sometimes, often, almost always. Abbreviation: MFIS-5, Modified Fatigue Impact Scale 5-item version.
Figure 2
Figure 2
Screenshot of graphic feedback of changes in fitness score (black line) and quality of life score (red line). Copyright © 2012, Curavista bv, Geertruidenberg, Netherlands. Reprinted with permission.
Figure 3
Figure 3
Numbers and percentages of patients who completed the MFIS-5 and LMSQoL questionnaires at the various time points from T0 to T12. Abbreviations: LMSQoL, Leeds Multiple Sclerosis Quality of Life; MFIS-5, Modified Fatigue Impact Scale 5-item version.
See this image and copyright information in PMC

References

    1. Polman CH, O’Connor PW, Havrdova E, et al. AFFIRM Investigators A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910. - PubMed
    1. Kappos L, Radue EW, O’Connor P, et al. FREEDOMS Study Group A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401. - PubMed
    1. O’Connor P, Wolinsky JS, Confavreux C, et al. TEMSO Trial Group Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293–1303. - PubMed
    1. Goodman AD, Brown TR, Krupp LB, et al. Fampridine MS-F203 Investigators Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373(9665):732–738. - PubMed
    1. Traboulsee A, Uitdehaag BMJ, Kappos L, et al. Measures of treatment adherence as prognostic factors for long-term outcomes in relapsing–remitting multiple sclerosis. P492. Mult Scler. 2010;16(Suppl 10):S165. - PMC - PubMed